GlaxoSmithKline got good news for its oncology research when its experimental drug for blood cancer received a “breakthrough” designation from the U.S. FDA.
The speedy regulatory review of GSK’s BCMA drug for multiple myeloma was also granted by the European Medicines Agency last month.
The drug’s promising Phase I clinical trial results will be discussed in detail on Dec. 11 at the annual meeting of the American Society of Hematology.
Read the Reuters coverage
